107 related articles for article (PubMed ID: 30033485)
21. FLAGIDA-lite is an effective regimen for patients between 70 and 80 years with acute myeloid leukemia or refractory anemia with excess blasts-2 and is feasible as outpatient treatment.
Bermúdez A; Pérez-Vázquez G; Insunza A; Baro J; Colorado M; Conde E; Díez-Gallarreta Z; Gutiérrez ML; López-Duarte M; Olalla I; Sanroma P; Yañez L; Iriondo A; Richard C
Am J Hematol; 2012 Jan; 87(1):42-4. PubMed ID: 22015963
[TBL] [Abstract][Full Text] [Related]
22. [Treating patients with acute myeloid leukemias (AML) according to the protocol of the AML-01.10 Russian multicenter randomized trial: the coordinating center's results].
Parovichnikova EN; Troitskaia VV; Kliasova GA; Kuz'mina LA; Sokolov AN; Paramonova EV; Galstian GM; Kessel'man SA; Drokov MIu; Vasil'eva VA; Obukhova TN; Kulikov SM; Savchenko VG
Ter Arkh; 2014; 86(7):14-23. PubMed ID: 25314773
[TBL] [Abstract][Full Text] [Related]
23. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial.
Burnett AK; Russell NH; Hills RK; Hunter AE; Kjeldsen L; Yin J; Gibson BE; Wheatley K; Milligan D
J Clin Oncol; 2013 Sep; 31(27):3360-8. PubMed ID: 23940227
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.
Xu J; Lv TT; Zhou XF; Huang Y; Liu DD; Yuan GL
Medicine (Baltimore); 2018 Sep; 97(39):e12102. PubMed ID: 30278488
[TBL] [Abstract][Full Text] [Related]
25. Results of IDA-FLAG programme in the treatment of recurrent acute myeloblastic leukaemia--preliminary report.
Łuczyński W; Muszyńska-Rosłan K; Krawczuk-Rybak M; Kuźmicz M; Iwaszkiewicz-Pawłowska A; Kaliszewski J
Med Sci Monit; 2001; 7(1):125-9. PubMed ID: 11208507
[TBL] [Abstract][Full Text] [Related]
26. A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75.
Reiffers J; Huguet F; Stoppa AM; Molina L; Marit G; Attal M; Gastaut JA; Michallet M; Lepeu G; Broustet A; Pris J; Maraninchi D; Hollard D; Fabères C; Mercier M; Hurteloup P; Danel P; Tellier Z; Berthaud P
Leukemia; 1996 Mar; 10(3):389-95. PubMed ID: 8642852
[TBL] [Abstract][Full Text] [Related]
27. A randomized comparison of immediate versus delayed application of G-CSF in induction therapy for patients with acute myeloid leukemia unfit for intensive chemotherapy.
von Lilienfeld-Toal M; Hahn-Ast C; Kirchner H; Flieger D; Dölken G; Glasmacher A
Haematologica; 2007 Dec; 92(12):1719-20. PubMed ID: 18056004
[TBL] [Abstract][Full Text] [Related]
28. Idarubicin plus cytarabine as first-line treatment of acute nonlymphoblastic leukemia.
Lambertenghi-Deliliers G; Annaloro C; Cortelezzi A; Cortellaro M; Della Volpe A; Maiolo AT; Mozzana R; Pogliani E; Pozzoli E; Polli EE
Semin Oncol; 1989 Feb; 16(1 Suppl 2):16-20. PubMed ID: 2928806
[No Abstract] [Full Text] [Related]
29. Risk-adapted induction and consolidation therapy in adults with de novo AML aged Heil G; Krauter J; Raghavachar A; Bergmann L; Hoelzer D; Fiedler W; Lübbert M; Noens L; Schlimok G; Arnold R; Kirchner H; Ganser A
Ann Hematol; 2004 Jun; 83(6):336-44. PubMed ID: 15034758
[TBL] [Abstract][Full Text] [Related]
30. Prospective, multicenter, phase II study on reducing the dosage of idarubicin and FLAG for patients younger than 65 years with resistant acute myeloid leukemia: a comparison with a higher dosage trial.
Kim H; Lee JH; Joo YD; Bae SH; Lee JH; Kim DY; Lee WS; Ryoo HM; Jo JC; Park JH; Lee KH
Acta Haematol; 2014; 132(1):87-96. PubMed ID: 24513865
[TBL] [Abstract][Full Text] [Related]
31. Acute monoblastic leukemia presenting with striking periorbital and periauricular infiltration.
Brierley CK; Eyre TA
Blood; 2017 Jun; 129(25):3396. PubMed ID: 28642361
[No Abstract] [Full Text] [Related]
32. High-dose cytarabine (24 g/m2) in combination with idarubicin (HiDAC-3) results in high first-cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemia.
Low M; Lee D; Coutsouvelis J; Patil S; Opat S; Walker P; Schwarer A; Salem H; Avery S; Spencer A; Wei A
Intern Med J; 2013 Mar; 43(3):294-7. PubMed ID: 22757980
[TBL] [Abstract][Full Text] [Related]
33. Predictors and short-term outcomes of hyperleukocytosis in children with acute myeloid leukemia: a report from the Children's Oncology Group.
Sung L; Aplenc R; Alonzo TA; Gerbing RB; Gamis AS;
Haematologica; 2012 Nov; 97(11):1770-3. PubMed ID: 22801969
[No Abstract] [Full Text] [Related]
34. [Treatment of acute myeloid leukemia -- a single center experience (2007-2013)].
Selmeczi A; Udvardy M; Illés A; Telek B; Kiss A; Batár P; Reményi G; Szász R; Ujj Z; Márton A; Ujfalusi A; Hevessy Z; Pinczés L; Bedekovics J; Rejtő L
Orv Hetil; 2014 Apr; 155(17):653-8. PubMed ID: 24755447
[TBL] [Abstract][Full Text] [Related]
35. Fractionated doses of gemtuzumab ozogamicin combined with 3 + 7 induction chemotherapy as salvage treatment for young patients with acute myeloid leukemia in first relapse.
Malfuson JV; Konopacki J; Thepenier C; Eddou H; Foissaud V; de Revel T
Ann Hematol; 2012 Dec; 91(12):1871-7. PubMed ID: 22820971
[TBL] [Abstract][Full Text] [Related]
36. [A late phase II comparative study of idarubicin + cytarabine and daunorubicin + cytarabine in adult patients with acute non-lymphocytic leukemia. Idarubicin Study Group].
Masaoka T; Ogawa M; Yamada K; Kimura K; Ohhashi Y
Gan To Kagaku Ryoho; 1993 Oct; 20(13):1995-2005. PubMed ID: 8215474
[TBL] [Abstract][Full Text] [Related]
37. Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
Liu H; Fu R; Li L; Wang G; Song J; Ruan E; Wang H; Wu Y; Wang X; Ding K; Shao Z
Clin Drug Investig; 2017 Feb; 37(2):167-174. PubMed ID: 27722823
[TBL] [Abstract][Full Text] [Related]
38. Breakthrough Fusarium solani infection in a patient with acute myeloid leukemia receiving posaconazole prophylaxis.
Wu CH; Lu PL; Hsiao HH; Liu TC; Lin SF; Chang CS; Hsu JF; Liu YC
Ann Hematol; 2014 Jun; 93(6):1079-81. PubMed ID: 24170227
[No Abstract] [Full Text] [Related]
39. Mini-ICE effectively mobilises peripheral blood stem cells after fludarabine-based regimens in acute myeloid leukaemia.
Mele A; Leopardi G; Sparaventi G; Nicolini G; D'Adamo F; Guiducci B; Barulli S; Malerba L; Stramigioli S; Talevi N; Politi P; Isidori A; Malagola M; Piccaluga P; Visani G
Eur J Haematol; 2005 Apr; 74(4):277-81. PubMed ID: 15777338
[TBL] [Abstract][Full Text] [Related]
40. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience.
Pastore D; Specchia G; Carluccio P; Liso A; Mestice A; Rizzi R; Greco G; Buquicchio C; Liso V
Ann Hematol; 2003 Apr; 82(4):231-5. PubMed ID: 12707726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
